Cargando…
Access to Guideline-Recommended Pharmacogenomic Tests for Cancer Treatments: Experience of Providers and Patients
Genomic tests are the fastest growing sector in medicine and medical science, yet there remains a dearth of research on access to pharmacogenomic tests and medications. The objective of this study is to explore providers’ and patients’ experiences and views on test access as well as strategies used...
Autores principales: | Wu, Ann Chen, Mazor, Kathleen M., Ceccarelli, Rachel, Loomer, Stephanie, Lu, Christine Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748629/ https://www.ncbi.nlm.nih.gov/pubmed/29140263 http://dx.doi.org/10.3390/jpm7040017 |
Ejemplares similares
-
The Implementation Process for Pharmacogenomic Testing for Cancer-Targeted Therapies
por: Wu, Ann Chen, et al.
Publicado: (2018) -
Insurance Coverage Policies for Pharmacogenomic and Multi-Gene Testing for Cancer
por: Lu, Christine Y., et al.
Publicado: (2018) -
Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000–2020)
por: Kim, Jeeyun A., et al.
Publicado: (2021) -
Physicians’ Knowledge, Attitude, and Experience of Pharmacogenomic Testing in China
por: Jia, Tong, et al.
Publicado: (2022) -
Clinical Pharmacists’ Involvement in Pharmacogenomics Testing and Related Services in China
por: Hu, Xiaowen, et al.
Publicado: (2022)